COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000 (MAESTRALE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01651455
Recruitment Status : Completed
First Posted : July 27, 2012
Last Update Posted : July 31, 2013
Sponsor:
Collaborator:
Medidata Solutions
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to describe two cohorts of cystic fibrosis patients treated in 2 different decades in terms of FEV1 (Forced Expiratory Volume in one second) maintenance.

Condition or disease
Cystic Fibrosis

Detailed Description:
The purpose of this study is to describe two cohorts of cystic fibrosis patients treated in terms of FEV1 maintenance from the age of 10 to 15 before and after 2000.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 92 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Maintaining Lung Function in Cystic Fibrosis Patients: Evaluation and Comparison Between Two Decades in a Retrospective Monocentric Observational Study
Study Start Date : September 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Cohort first decade
Patients born between 01/01/1979 and 12/31/1984
Cohort second decade
Patients born between 01/01/1991 and 12/31/1996


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To describe the difference in terms of FEV1 decline between two cohorts of cystic fibrosis patients [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. To identify clinical parameters or treatments correlated to FEV1 maintenance in two cohorts of cystic fibrosis patients [ Time Frame: 5 years ]
  2. To evaluate the number of patients with Pseudomonas Aeruginosa infection during observational period [ Time Frame: 5 years ]
  3. To describe length of time without Pseudomonas A. infection in non-colonized patients during observational period. [ Time Frame: 5 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients affected with Pseudomonas A. living in the N-E area of Italy.
Criteria

Inclusion Criteria:

  • Patients with Cystic Fibrosis diagnosed with neo-natal screening
  • Patients born between 01/01/1979 and 12/31/1984 (Cohort 1)and patients born between 01/01/1991 and 12/31/1996 (Cohort 2)
  • Patients with at least 2 FEV1 yearly measurements from the age of 10 to 15

Exclusion Criteria:

  • Patients with malignant tumor
  • Patients with meconium ileus
  • Patients with transplantation (pneumectomy or lobectomy)
  • Patients involved in any other clinical trial
  • Patients moved to another Clinical Center
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01651455


Locations
Layout table for location information
Italy
U.O. Azienda Ospedaliera
Verona, Veneto, Italy, 37126
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Medidata Solutions
Investigators
Layout table for investigator information
Principal Investigator: Baroukh Maurice Assael, Professor U.O. Fibrosi Cistica Azienda Ospedaliera Verona
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT01651455    
Other Study ID Numbers: MAESTRALE
First Posted: July 27, 2012    Key Record Dates
Last Update Posted: July 31, 2013
Last Verified: July 2013
Keywords provided by Chiesi Farmaceutici S.p.A.:
Cystic Fibrosis
Pseudomonas Aeruginosa
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
 Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases